Although PgR expression alone has historical precedence as a clinical prognosticator of breast cancer patient in response to hormone therapy [8], [51], [52], the analysis showed that GREB1 mRNA predicts disease-free survival (DFS) in Tamoxifen-treated patients better than PgR or ER (Table 1). The gene discussed is GREB1; the disease is breast carcinoma.